Cost-benefit analysis a dominant tool in healthcaredoi:10.1007/BF03277218NoneSpringer International PublishingPharmacoeconomics & Outcomes News Weekly
关键词: cost-benefit analysis cost-effectiveness analysis cost-utility analysis exercise fitness health economics healthcare intervention promotion DOI: 10.1080/14034940600627853 被引量: 132 年份: 2006 收藏 引用 批量引用 报错 分享 全部来源 求助全文 全文购买 万方医学 dx.doi.org Europe PMC NCBI ...
Cost-benefit analysis (CBA) is defined in the methodology literature as a form of economic evaluation in which both costs and consequences are measured in monetary terms. In recent years we have witnessed renewed enthusiasm for CBA and the use of willingness to pay (WTP) as a method of measu...
A diagram of decision-making by health consumers at different GHE price levels under two cases, with and without health insurance. A: Insured health consumers are more likely to pay for GHE when the cost is low. B: Uninsured health consumers, by contrast, are more inclined to pay for GHE ...
关键词: Health Care Rationing Social Justice Health Policy Socioeconomic Factors Cost-Benefit Analysis Health Services Research Delivery of Health Care Outcome Assessment (Health Care Great Britain DOI: 10.3310/hta5030 被引量: 347 年份: 2001
Typically, health benefit cost-growth runs higher than general inflation. According to Sunit Patel, chief health actuary at Mercer, 2022 is an anomaly because employer health plan sponsors haven't yet felt the full impact of inflation.
Objectives Multimodal rehabilitation programs (MMRPs) have been shown to be both cost-effective and an effective method for managing chronic pain in specialist care. However, while the vast majority of patients are treated in primary healthcare, MMRPs ar
Thus, we often encounter views that call for thorough research on the efficiency of spending resources on healthcare, such as the value-for-money approach and cost–benefit analysis [8]. This research concerns the efficiency of the European Union (EU) countries. In addition, research is ...
In the U.S., private insurers can negotiate drug prices with manufacturers, often through the services ofpharmacy benefit managers. However, Medicare, which pays for a hefty percentage of the national drug costs, is not permitted to negotiate prices with manufacturers. ...
Companies solving those challenges will benefit from cost savings realized through AI-based optimization of their processes, their capacity and asset management as well as from improved diagnostics and personalized treatments that secure higher quality in treatments. ...